Assessing the evidence on remdesivir.
作者信息
Núñez Isaac, Soto-Mota Adrian
机构信息
Department of Medical Education, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 14080, Mexico.
Metabolic Diseases Research Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 14080, Mexico.
出版信息
Lancet Infect Dis. 2021 Dec;21(12):1630. doi: 10.1016/S1473-3099(21)00693-9.
Abstract
摘要
相似文献
1
Assessing the evidence on remdesivir.评估关于瑞德西韦的证据。
Lancet Infect Dis. 2021 Dec;21(12):1630. doi: 10.1016/S1473-3099(21)00693-9.
2
[Remdesivir for patients with severe COVID-19].[瑞德西韦用于重症新型冠状病毒肺炎患者]
Internist (Berl). 2020 Jun;61(6):644-645. doi: 10.1007/s00108-020-00800-5.
3
Remdesivir Use in COVID-19 Patients: Cutaneous Adverse Effect or Disease Manifestation?瑞德西韦在新冠肺炎患者中的应用：皮肤不良反应还是疾病表现？
J Drugs Dermatol. 2021 May 1;20(5):575. doi: 10.36849/JDD.5777.
4
Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?我们用瑞德西韦（一种老药新包装）找到了治疗新冠病毒肺炎的万灵药了吗？
J R Coll Physicians Edinb. 2020 Jun;50(2):159-161. doi: 10.4997/JRCPE.2020.217.
5
Weinreb Amide Approach to the Practical Synthesis of a Key Remdesivir Intermediate.威伦贝酰胺法在瑞德西韦关键中间体的实用合成中的应用。
J Org Chem. 2021 Apr 2;86(7):5065-5072. doi: 10.1021/acs.joc.0c02986. Epub 2021 Mar 18.
6
Remdesivir: An Antiviral Still Seeking a Raison d'Être.瑞德西韦：一种仍在探寻存在意义的抗病毒药物。
Clin Infect Dis. 2021 Nov 16;73(10):1857-1859. doi: 10.1093/cid/ciab220.
7
Does remdesivir have any neuropsychiatric adverse effects?瑞德西韦有任何神经精神方面的不良反应吗？
Ir J Psychol Med. 2021 Dec;38(4):313-314. doi: 10.1017/ipm.2020.67. Epub 2020 Jul 9.
8
The Goldilocks Time for Remdesivir - Is Any Indication Just Right?瑞德西韦的“刚好合适”时机——有合适的迹象吗？
N Engl J Med. 2022 Jan 27;386(4):385-387. doi: 10.1056/NEJMe2118579. Epub 2021 Dec 22.
9
Remdesivir and Potential Interactions With Psychotropic Medications: A COVID-19 Perspective.瑞德西韦及其与精神药物的潜在相互作用：从COVID-19角度看
Prim Care Companion CNS Disord. 2020 May 28;22(3):20com02664. doi: 10.4088/PCC.20com02664.
10
Remdesivir: Preliminary Data and Clinical Use Versus Recommended Use.
Pediatrics. 2021 May;147(5). doi: 10.1542/peds.2021-050212.
引用本文的文献
1
A review of clinical efficacy data supporting emergency use authorization for COVID-19 therapeutics and lessons for future pandemics.支持 COVID-19 治疗药物紧急使用授权的临床疗效数据综述及对未来大流行的启示。
Clin Transl Sci. 2022 Oct;15(10):2279-2292. doi: 10.1111/cts.13384. Epub 2022 Aug 21.
2
Hospitalization as an outcome in ambulatory COVID-19 trials-not applicable in every setting.住院作为门诊COVID-19试验的一个结果——并非在每种情况下都适用。
Clin Microbiol Infect. 2022 Sep;28(9):1187-1188. doi: 10.1016/j.cmi.2022.05.026. Epub 2022 May 30.
3
Estimation Model for Healthcare Costs and Intensive Care Units Access for Covid-19 Patients and Evaluation of the Effects of Remdesivir in the Portuguese Context: Hypothetical Study.Covid-19 患者医疗费用和重症监护病房使用的估算模型及在葡萄牙环境下评估瑞德西韦效果的研究：假设研究。
Clin Drug Investig. 2022 Apr;42(4):345-354. doi: 10.1007/s40261-022-01128-8. Epub 2022 Mar 17.
本文引用的文献
1
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.瑞德西韦联合标准治疗与单纯标准治疗用于治疗因 COVID-19 住院的患者（DisCoVeRy）：一项 3 期、随机、对照、开放标签试验。
Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14.
2
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
3
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
4
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
Zotero 插件